| Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective … A Carmona-Bayonas, P Jiménez-Fonseca, J Virizuela Echaburu, ... Journal of Clinical Oncology 33 (5), 465-471, 2015 | 191 | 2015 |
| Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer U Malapelle, R Sirera, E Jantus-Lewintre, P Reclusa, S Calabuig-Fariñas, ... Expert review of molecular diagnostics 17 (3), 209-215, 2017 | 190 | 2017 |
| Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial C Camps, B Massuti, A Jimenez, I Maestu, RG Gómez, D Isla, ... Annals of Oncology 17 (3), 467-472, 2006 | 172 | 2006 |
| Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer R Sirera, RM Bremnes, A Cabrera, E Jantus-Lewintre, E Sanmartín, ... Journal of Thoracic Oncology 6 (2), 286-290, 2011 | 111 | 2011 |
| Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer L Puchades-Carrasco, E Jantus-Lewintre, C Pérez-Rambla, ... Oncotarget 7 (11), 12904, 2016 | 102 | 2016 |
| Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study Y Escobar, G Cajaraville, JA Virizuela, R Álvarez, A Muñoz, O Olariaga, ... Supportive Care in Cancer 23, 2833-2840, 2015 | 102 | 2015 |
| Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer A Herreros-Pomares, JD de-Maya-Girones, S Calabuig-Fariñas, R Lucas, ... Cell death & disease 10 (9), 660, 2019 | 96 | 2019 |
| Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC E Jantus-Lewintre, E Sanmartín, R Sirera, A Blasco, JJ Sanchez, M Tarón, ... Lung Cancer 74 (2), 326-331, 2011 | 81 | 2011 |
| Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? C Camps, R Sirera, R Bremnes, A Blasco, E Sancho, P Bayo, MJ Safont, ... Lung cancer 50 (3), 339-346, 2005 | 81 | 2005 |
| Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions S Villatoro, C Mayo‐de‐las‐Casas, N Jordana‐Ariza, S Viteri‐Ramírez, ... Molecular oncology 13 (12), 2633-2645, 2019 | 79 | 2019 |
| SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC)(2019) M Dómine, T Moran, D Isla, JL Martí, I Sullivan, M Provencio, ME Olmedo, ... Clinical and Translational Oncology 22, 245-255, 2020 | 70 | 2020 |
| The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients C Camps, E Jantus-Lewintre, A Cabrera, A Blasco, E Sanmartín, ... Lung Cancer 72 (3), 365-369, 2011 | 70 | 2011 |
| SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016) M Muñoz, A Santaballa, MA Seguí, C Beato, S De La Cruz, J Espinosa, ... Clinical and Translational Oncology 18, 1229-1236, 2016 | 65 | 2016 |
| Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients J Garde-Noguera, P Martin-Martorell, M De Julián, J Perez-Altozano, ... Clinical and translational oncology 20, 1072-1079, 2018 | 62 | 2018 |
| Importance of quality of life in patients with non–small-cell lung cancer C Camps, N del Pozo, A Blasco, P Blasco, R Sirera Clinical lung cancer 10 (2), 83-90, 2009 | 62 | 2009 |
| Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology A Goday, I Barneto, JM García-Almeida, A Blasco, A Lecube, C Grávalos, ... Clinical and Translational Oncology 17, 763-771, 2015 | 61 | 2015 |
| Lung cancer symptoms at diagnosis: results of a nationwide registry study A Ruano-Ravina, M Provencio, VC De Juan, E Carcereny, T Moran, ... ESMO open 5 (6), e001021, 2020 | 58 | 2020 |
| Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non–small-cell lung cancer with untreated brain metastases (Atezo … E Nadal, D Rodríguez-Abreu, M Simó, B Massutí, O Juan, G Huidobro, ... Journal of Clinical Oncology 41 (28), 4478-4485, 2023 | 46 | 2023 |
| A consensus statement on the gender perspective in lung cancer D Isla, M Majem, N Viñolas, A Artal, A Blasco, E Felip, P Garrido, J Remón, ... Clinical and Translational Oncology 19, 527-535, 2017 | 46 | 2017 |
| Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers M Usó, E Jantus-Lewintre, RM Bremnes, S Calabuig, A Blasco, E Pastor, ... Oncotarget 7 (33), 52849, 2016 | 45 | 2016 |
Carlos CampsProfessor MedicineBestätigte E-Mail-Adresse bei gva.es
